FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
Status:
Active, not recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies fluorothymidine F 18 (FLT) positron emission tomography
(PET)/computed tomography (CT) in measuring response in patients with previously untreated
acute myeloid leukemia. FLT is a radioactive substance that may "light up" where cancer is in
the body. FLT is injected into the blood and builds up in cells that are dividing, including
cancer cells. Diagnostic procedures, such as PET/CT, may help measure a patient's response to
earlier treatment.